Abstract
Tositumomab (Bexxar®, Corixa, GSK) is a murine IgGλ2a monoclonal antibody directed to the CD20 antigen expressed by normal and primate B lymphocytes, and on human malignant B cells. In the therapeutic regimen it is usually associated with tositumomab-Iodine131 to exert anti-neoplastic radioimmunotherapeutic effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tositumomab (Bexxar®) BLA 125011 Medical Review FDA, June 2003
Tositumomab (Bexxar®) BLA 125011/S024 Medical Review Dec 2004
Tositumomab (Bexxar®) Product Monograph GSK, Canada Dec 2007
Tositumomab (Bexxar®) Prescribing Information GSK, Aug 2012
Boross P, Leusen JHW (2012) Mechanisms of action of anti CD20 antibodies. Am J Cancer Res 2:676–690
Lim SH, Vaughan AT, Ashton-Key M et al (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118:2530–2540
Buchegger F, Antonescu C, Helg C et al (2011) Six of twelve relapsed or refractory indolent lymphoma patients treated 10 years ago with 131Iodine-tositumomab remain in complete remission. J Nucl Med 52:896–900
Link BK, Martin P, Kaminski SJ et al (2010) Cyclophosphamide, vincristine, and prednisone followed by tositumomab and Iodine-131–tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol 28:3035–3041
Hattori N, Gopal AK, Shields AT et al (2012) 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin’s lymphoma: radiation dose to the testes. Nuclear Med 33:1225–1231
Press OW, Unger JM, Rimsza LM et al (2012) Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131Iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol. doi:10.1200/JCO.2012.42.4101
Smith K, Byer G, Morris CG et al (2012) Outcomes of patients with non-Hodgkin’s lymphoma treated with Bexxar with or without external-beam radiotherapy. Int J Radiat Oncol Biol Phys 82:1122–1127
Tositumomab (Bexxar®) Briefing Package for ODAC Meeting, GSK February 2011
Persky DO, Dornan D, Goldman B et al (2012) Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone. Haematologica 97(6):937–942 doi:10.3324/haematol.2011.050419
Hammadi M, Youinou P, Tempescul A et al (2011) Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells. Haematologica 96(3):400–407 doi:10.3324/haematol.2011.051938
Author information
Authors and Affiliations
Corresponding author
1 Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Copyright information
© 2014 Springer-Verlag Italia
About this chapter
Cite this chapter
Tridente, G. (2014). Tositumomab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_37
Download citation
DOI: https://doi.org/10.1007/978-88-470-5313-7_37
Published:
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-5312-0
Online ISBN: 978-88-470-5313-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)